The ALL Hub was pleased to speak with Claire Roddie, University College London Cancer Institute, London, UK. We asked, where does obecabtagene autoleucel (obe-cel) currently fit in the treatment algorithm for B-cell acute lymphoblastic leukemia (B-cell ALL), and how might this evolve?

In this interview, Roddie discusses the current regulatory approvals for obe-cel for the treatment of B-cell ALL and the key findings from the phase Ib/II FELIX trial. Roddie also outlines the evolving role of obe-cel in the treatment of ALL, including ongoing studies investigating its use earlier in the treatment paradigm, and concludes by highlighting the importance of developing biomarker assays to monitor patients following CAR T-cell infusion.

This educational resource is independently supported by Autolus. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub was pleased to speak with Ibrahim Aldoss, City of Hope, Duarte, US. We asked, What are the recommendations for addressing challenges in implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)?

In this interview, Aldoss discusses the challenges associated with implementing asparaginase-based regimens in AYA patients with ALL and shares recommendations to overcome them, which were recently established and published by a US consensus panel.

This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub spoke with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children’s Hospital, Salt Lake City, US. We asked, What are the main barriers associated with implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with ALL.

In this interview, Maese discussed the main challenges faced when treating AYA patients with ALL and the difficulties associated with facilitating the implementation of asparaginase-based regimens to treat this patient population.

This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.